A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
A. M. Di Giacomo
No relevant relationships to disclose
P. A. Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
E. Fonsatti
No relevant relationships to disclose
E. Pittiglio
No relevant relationships to disclose
P. Queirolo
No relevant relationships to disclose
L. Pilla
No relevant relationships to disclose
R. Ridolfi
No relevant relationships to disclose
M. Santinami
No relevant relationships to disclose
A. Testori
Consultant or Advisory Role - Bristol-Myers Squibb
G. Parmiani
Honoraria - Italian Network for Tumor Biotherapy
M. Maio
Consultant or Advisory Role - Bristol-Myers Squibb